| Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will participate in a fireside chat and be available for one-on-one meetings throughout the event. |
businesswire.com |
2025-05-16 14:53:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025. Recent Corporate Highlights Announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose (LD) IL-2 and CTLA4-Ig combination treatment in pa. |
businesswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025 |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in two upcoming conferences in May 2025. Chief Executive Officer Arun Swaminathan, Ph.D. and Chief Financial Officer David Snyder will be available for one-on-one meetings with registered investors of the following conferences: Event: D. Boral Capital Inaug. |
businesswire.com |
2025-05-08 12:15:00 |
Czytaj oryginał (ang.) |
| Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors |
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of challenging therapeutic areas. |
globenewswire.com |
2025-05-08 09:00:00 |
Czytaj oryginał (ang.) |
| Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? |
Here is how Coya Therapeutics, Inc. (COYA) and Doximity (DOCS) have performed compared to their sector so far this year. |
zacks.com |
2025-04-29 14:40:22 |
Czytaj oryginał (ang.) |
| Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release |
Positive interim data by Coya Therapeutics released from 5 patients in an investigator-initiated proof-of-concept study using COYA-302 for the treatment of patients with FTD. An IND filing and phase 2b initiation of COYA-302 to treat FTD patients expected in the 2nd half of 2025. It is said that the 7 major markets for the Frontotemporal Dementia market is expected to reach $596.3 million by 2034. |
seekingalpha.com |
2025-04-25 15:27:12 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurol. |
businesswire.com |
2025-04-24 12:15:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? |
The consensus price target hints at a 144.7% upside potential for Coya Therapeutics, Inc. (COYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-04-23 14:55:34 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced publication of the results of a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya's investigational biologic combination to suppress pro-inflammatory myeloid cells, enhance Treg suppressive function, and modulate T cell proliferation, in an in vit. |
businesswire.com |
2025-04-21 13:51:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer's disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna. The presentation, titled, “A Phase II. |
businesswire.com |
2025-04-01 12:15:00 |
Czytaj oryginał (ang.) |
| What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock |
Coya Therapeutics, Inc. (COYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-27 15:01:07 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet |
The consensus price target hints at a 149.6% upside potential for Coya Therapeutics, Inc. (COYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-03-27 12:55:30 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today provides a status update of its investigational regulatory T cell-derived exosome (Treg exosomes) platform intended for the treatment of systemic and neurodegenerative diseases driven by chronic inflammation. Sustained inflammatory responses driven by dysfunctional immune regulation is. |
businesswire.com |
2025-03-26 10:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Ph. |
businesswire.com |
2025-03-18 10:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast “Is Alzheimer's next for GLP-1s and Combos?” on February 27, 2025 to discuss the potential treatment of Al. |
businesswire.com |
2025-02-25 10:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD |
Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically combines low-dose IL-2 and CTLA4-Ig, and it's now progressing toward Phase 2 trials for ALS and FTD. COYA 301 was intended for AD, but its mixed Phase 2 results may be why COYA is now pivoting toward COYA 302. |
seekingalpha.com |
2025-02-07 19:17:56 |
Czytaj oryginał (ang.) |
| Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch |
Potential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data from proof-of-concept study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in Q2 of 2025. The global Amyotrophic Lateral Sclerosis market is expected to reach $1.33 billion by 2033. |
seekingalpha.com |
2025-02-07 15:53:05 |
Czytaj oryginał (ang.) |
| Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing |
On Thursday, Coya Therapeutics, Inc. COYA announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer's disease (AD). |
benzinga.com |
2025-02-06 15:30:12 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced encouraging blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer's disease (AD). Statistically significant reduced levels of proinflammatory markers were observed in patients. |
businesswire.com |
2025-02-06 10:00:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital. Toplin. |
businesswire.com |
2024-12-18 10:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 – 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55. |
businesswire.com |
2024-11-25 10:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024. Recent Corporate Highlights Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's. |
businesswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1, 2024. Dr. Swaminathan was instrumental in executing several significant commercial transactions in his career, including Coya's licensing transaction w. |
businesswire.com |
2024-11-01 10:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off |
Coya Therapeutics, Inc.'s stock has sold off on misinterpreted data from a small trial with COYA 301. The presented clinical data validates safety, tolerability, and the inverse dose response of IL-2 and Treg function. The much more efficacious COYA 302 is Coya's actual therapy candidate. |
seekingalpha.com |
2024-10-31 12:31:56 |
Czytaj oryginał (ang.) |
| Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study |
On Tuesday, Coya Therapeutics, Inc. COYA released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease. |
benzinga.com |
2024-10-29 16:36:52 |
Czytaj oryginał (ang.) |
| Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial |
Coya Therapeutics said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent neuroinflammation in patients with Alzheimer's disease enrolled in a small, mid-stage trial. |
reuters.com |
2024-10-29 08:41:57 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain) |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease were announced today at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The study was led by Dr. Alireza Faridar an. |
businesswire.com |
2024-10-29 08:30:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts |
Coya Therapeutics is developing treatments for neurodegenerative diseases, with its lead drug COYA 302 showing promising early results in ALS trials. Despite recent delays, the adverse investor reaction presents an investment opportunity as the company progresses on its pipeline development. The partnership with Dr. Reddy's Labs validates COYA 302 and provides a mechanism for rapid commercial scaling upon FDA approval. |
seekingalpha.com |
2024-10-13 08:17:50 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chairman and CEO Howard Berman, Ph.D. has been recognized as a PharmaVoice 100 winner in the category of Biotech Pathfinders. The annual list recognizes the most inspiring people in the life sciences industry and is a another recognition of Dr. Berman's impact as Coya's CEO as. |
businesswire.com |
2024-10-08 13:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announces that data from the IIT, a double-blind, placebo-controlled, phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer's Disease, conducted at Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer's Association w. |
businesswire.com |
2024-08-02 12:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives. The development and production of exosomes from patients' regulatory T cells will be funded by the Johnson. |
businesswire.com |
2024-06-20 12:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the publication of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neur. |
businesswire.com |
2024-06-11 12:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer |
Coya Therapeutics is set to initiate a Phase 2 trial in ALS and release the topline results of a Phase 2 trial in Alzheimer's disease in the summer. The company's anti-inflammatory approach has received strong external validation. Recently, small open-label clinical trials in ALS and Alzheimer's have shown improvement or disease stabilization. |
seekingalpha.com |
2024-06-10 18:55:09 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neuro. |
businesswire.com |
2024-06-03 12:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that MSCI has selected the Company's shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024. The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 const. |
businesswire.com |
2024-05-28 12:15:00 |
Czytaj oryginał (ang.) |
| 7 Biotech Stocks to Put on Your Breakthrough Radar |
For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first. |
investorplace.com |
2024-05-27 16:32:15 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the completion of a randomized, double-blind, placebo-controlled Phase 2 study of LD IL-2 in patients with mild-to-moderate AD. The study is being conducted by Drs. Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheim. |
businesswire.com |
2024-05-22 12:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF) |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the Alzheimer's Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company's common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million. The ADDF's mission is to rapidly accelerate the development of drugs to prevent, trea. |
businesswire.com |
2024-05-20 12:15:00 |
Czytaj oryginał (ang.) |
| Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results |
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024. Recent Corporate Highlights Announced successful pre-IND and Type C meetings with FDA in January 2024 to advance the development of COYA 302 for the treatment of ALS; IND expected to be file. |
businesswire.com |
2024-05-09 20:10:00 |
Czytaj oryginał (ang.) |